Details for Patent: RE46604

Which drugs does patent RE46604 protect, and when does it expire?

Patent RE46604 protects HETLIOZ and is included in one NDA.

This patent has one hundred and thirty-five patent family members in twenty-two countries.

Summary for Patent: RE46604

Title:	Treatment of circadian rhythm disorders
Abstract:	Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Inventor(s):	Dressman; Marlene Michelle (Germantown, MD), Feeney; John Joseph (Olney, MD), Licamele; Louis William (Potomac, MD), Polymeropoulos; Mihael H. (Potomac, MD)
Assignee:	VANDA PHARMACEUTICALS, INC. (Washington, DC)
Application Number:	15/051,978
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent RE46604
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent RE46604

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014	AB	RX	Yes	Yes						TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME

International Family Members for US Patent RE46604

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013211878
Australia	2013211880
Australia	2013361459
Australia	2015206797
Australia	2016204178